

# NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

## TREATMENT SETTINGS

## NCCN GUIDELINES® PREFERRED REGIMEN OPTIONS

**First-line therapy**  
CLL/SLL  
**Without**  
del(17p)/TP53 mutation

acalabrutinib  
+  
obinutuzumab  
(category 1)

venetoclax  
+  
obinutuzumab  
(category 1)

zanubrutinib  
(category 1)

**Second-line or  
third-line therapy**  
CLL/SLL  
**Without**  
del(17p)/TP53 mutation

acalabrutinib  
(category 1)

zanubrutinib  
(category 1)

venetoclax  
+  
rituximab  
(category 1)

**First-line therapy**  
CLL/SLL  
**With**  
del(17p)/TP53 mutation

acalabrutinib  
+  
obinutuzumab  
(category 2A)

venetoclax  
+  
obinutuzumab  
(category 2A)

zanubrutinib  
(category 2A)

**Second-line and  
subsequent therapy**  
CLL/SLL  
**With**  
del(17p)/TP53 mutation

acalabrutinib  
(category 1)

venetoclax  
+  
rituximab  
(category 1)

venetoclax  
(category 2A)

zanubrutinib  
(category 1)

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

NCCN = National Comprehensive Cancer Network® (NCCN®).

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed January 25, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org.

For more information, please  
visit [www.BeiGene.com](http://www.BeiGene.com)



BeiGene is a registered trademark owned by BeiGene, Ltd or its affiliates.  
© BeiGene, Ltd. 2023 All Rights Reserved. 0922-NP-PRC-009r1 02/23